Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)
Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)
复制标题
DOI：
10.1080/07357900902849699
复制
发表时间：
2009-01-01
影响因子：
2.4
通讯作者：
Patel, Firuza D.
中科院分区：
文献类型：
--
作者：
Chaudhry, Parvesh;Srinivasan, Radhika;Patel, Firuza D.
目的是确定BRCA1、MGMT、MLH1、RASSF1A和p16基因的启动子甲基化是否能够预测对铂类化疗的反应。招募了35名接受铂类化疗的上皮性卵巢癌（EOC）患者。进行了甲基化特异性聚合酶链反应，并得出了甲基化指数（MI）。通过临床、影像学以及连续的CA125水平记录对铂类化疗的反应。甲基化的BRCA1（p = 0.037）和较高的MI（p = 0.045）与原发性化疗敏感性相关。较高的MI可预测更好的预后（p = 0.032）。在上皮性卵巢癌中，BRCA1基因启动子甲基化有助于预测对化疗的反应。
The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy. Thirty-five subjects with epithelial ovarian cancer (EOC) treated by platinum-based chemotherapy were recruited. Methylation-specific polymerase chain reaction was carried out and the methylation index (MI) was also derived. Response to platinum-based chemotherapy was documented clinically, radiologically, and by serial CA125 levels. Methylated BRCA1 (p = .037) and a higher MI (p = .045) were associated with primary chemosensitivity. A better outcome was predicted by a higher MI (p = .032). In EOC, BRCA1 gene promoter methylation is useful in the prediction of response to chemotherapy.